Disc Medicine Inc (IRON) reported disappointing financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) stood at $-1.77, falling short of Wall Street's consensus estimate of $-1.49 by $0.28. Revenue remained at $0.0B, matching expectations but signaling challenges in the company’s operational performance.
The announcement highlights the ongoing struggles Disc Medicine faces as a clinical-stage biopharmaceutical company focused on developing treatments for hematologic diseases. With a market cap of $3,136.2 million and an EPS of $-4.47 over the trailing twelve months, the company is navigating a competitive landscape.
Management will host an earnings conference call at bmo to discuss these results and provide further insights into the company's performance and future outlook. Investors are encouraged to review the full earnings release and listen to management commentary for a comprehensive understanding of the quarter's performance.
Looking ahead, the company is set to report its next earnings on May 4, 2026, with an EPS estimate of $-1.6943 and revenue expectations remaining at $0.0B. This update provides insight into Disc Medicine Inc's current financial health as it continues to advance its pipeline, which includes treatments for conditions such as erythropoietic porphyrias and Diamond-Blackfan Anemia.